Skip to main content
ACROBIOSYSTEMS CO.,LTD. logo

ACROBIOSYSTEMS CO.,LTD. — Investor Relations & Filings

Ticker · 301080 ISIN · CNE100004S13 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 609 across all filing types
Latest filing 2026-05-21 Share Issue/Capital Cha…
Country CN China
Listing Shenzhen Stock Exchange 301080

About ACROBIOSYSTEMS CO.,LTD.

https://www.acrobiosystems.cn

ACROBIOSYSTEMS CO.,LTD. is a global biotechnology company specializing in the development and manufacturing of high-quality recombinant proteins and critical reagents for the life sciences industry. The company provides a comprehensive portfolio of products designed to accelerate the development of target therapeutics, including antibodies, cell and gene therapies, and vaccines. Key offerings include a wide range of biotinylated proteins, enzymes, and assay kits characterized by high bioactivity and batch-to-batch consistency. ACROBIOSYSTEMS supports drug discovery and clinical development through specialized platforms for protein engineering and characterization. Its products serve a diverse client base of pharmaceutical companies, biotechnology firms, and academic research institutions worldwide, focusing on therapeutic areas such as oncology, immunology, and infectious diseases.

Recent filings

Filing Released Lang Actions
董事会薪酬与考核委员会关于公司2025年限制性股票激励计划预留授予激励对象名单（预留授予日）的核查意见
Share Issue/Capital Change Classification · 82% confidence The document is an official board committee announcement regarding the reserved grant list for the company’s 2025 restricted stock incentive plan. It relates to the issuance of shares under an equity incentive scheme, not a management change, earnings release, or proxy materials. Therefore it falls under “Share Issue/Capital Change” (SHA).
2026-05-21 Chinese
关于调整2025年限制性股票激励计划首次及预留限制性股票授予价格及数量的公告
Transaction in Own Shares Classification · 82% confidence The document is a corporate announcement by Beijing Biosystems (百普赛斯) regarding adjustments to the grant price and quantities under its 2025 restricted stock incentive plan (“股权激励计划”). It details the board and shareholder approvals, the calculation formulas to adjust price and share quantities following dividends and bonus share distributions, and confirms necessary legal opinions. This relates directly to the issuance and adjustment of the company’s own shares under an equity incentive program, fitting the definition of a Transaction in Own Shares (POS).
2026-05-21 Chinese
上海市通力律师事务所关于北京百普赛斯生物科技股份有限公司2023年限制性股票激励计划作废部分已授予尚未归属的限制性股票相关事项之法律意见书
Regulatory Filings Classification · 80% confidence The document is a legal opinion letter issued by a law firm regarding the cancellation of unvested restricted stock under a 2023 incentive plan for Beijing百普赛斯生物科技股份有限公司. It contains legal analysis and conclusions, not actual financial statements or an audit report, nor is it a meeting transcript or earnings release. It is not a proxy statement nor an executive compensation schedule. As a miscellaneous regulatory submission accompanying corporate disclosures, it best fits the fallback category “Regulatory Filings” (RNS).
2026-05-21 Chinese
第二届董事会第二十六次会议决议公告
Share Issue/Capital Change Classification · 55% confidence The document is a “Board of Directors Meeting Resolution Announcement” disclosing approval of adjustments and grants under the company’s restrictive stock incentive plans. It is not a full financial report, earnings release, management change notice, or proxy statement. These stock incentive grants constitute a change in share capital (new restricted shares to be issued), fitting the Share Issue/Capital Change category (SHA).
2026-05-21 Chinese
2025年限制性股票激励计划预留授予部分激励对象名单（预留授予日）
Share Issue/Capital Change Classification · 85% confidence The document is an announcement by the board of Beijing Bioprocess Biotechnology Co., Ltd. detailing the allocation of new restricted stock under its 2025 equity incentive plan, listing individual grantees, share quantities, and percentages of total share capital. This clearly relates to a capital change via new share issuance rather than a financial report, management discussion, or regulatory certification. Therefore, it falls under the “Share Issue/Capital Change” category (SHA).
2026-05-21 Chinese
上海君澜律师事务所关于北京百普赛斯生物科技股份有限公司调整2025年限制性股票激励计划及向激励对象授予预留部分限制性股票之法律意见书
Regulatory Filings Classification · 85% confidence The document is a legal opinion letter (“法律意见书”) issued by a law firm addressing the adjustment and grant of a 2025 restricted stock incentive plan. It does not contain financial statements, earnings data, or management’s own analysis of results, nor does it serve as an investor presentation, proxy solicitation, or remuneration disclosure form. Rather, it is a compliance/legal attestation required for regulatory filings. Under the guidelines, legal opinions and attestation letters are classified as Regulatory Filings (RNS).
2026-05-21 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.